白血病
癌症研究
淋巴瘤
埃尔特罗姆博帕格
医学
免疫学
血小板
免疫性血小板减少症
作者
Connie L. Erickson‐Miller,Jennifer Kirchner,Manuel Aivado,Richard May,Parrish L. Payne,Antony Chadderton
标识
DOI:10.1016/j.leukres.2010.02.005
摘要
Leukemia cell lines were treated with eltrombopag or thrombopoietin and their proliferative response was determined. Eltrombopag did not increase proliferation of cell lines that did not express high levels of megakaryocyte markers. Instead, treatment with eltrombopag alone inhibited proliferation of many cell lines (IC(50) range=0.56-21 microg/mL). The addition of other cytokines, such as G-CSF, Epo or Tpo, did not affect the decrease in proliferation. The decrease in proliferation appears to be through a TpoR-independent, nonapoptotic mechanism. These findings suggest that eltrombopag does not enhance, but rather inhibits, proliferation of leukemia cell lines in vitro.
科研通智能强力驱动
Strongly Powered by AbleSci AI